Sangui Biotech International, Inc., often referred to as Sangui Biotech, is a pioneering company headquartered in Delaware, USA. Founded in 2001, the firm operates primarily in the biotechnology sector, focusing on innovative solutions for medical and therapeutic applications. With a commitment to advancing healthcare, Sangui Biotech has developed a range of unique products, including cutting-edge blood substitutes and advanced wound care technologies. The company has achieved significant milestones, positioning itself as a leader in the field of biopharmaceuticals. Its core offerings are distinguished by their ability to enhance patient outcomes and improve quality of life. With a strong presence in both domestic and international markets, Sangui Biotech continues to drive innovation and maintain a competitive edge in the rapidly evolving biotechnology landscape.
How does Sangui Biotech International, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Sangui Biotech International, Inc.'s score of 20 is lower than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Sangui Biotech International, Inc., headquartered in Delaware, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and climate commitments suggests that Sangui Biotech may not yet have established a formal framework for addressing its carbon footprint or engaging in sustainability initiatives. As the industry increasingly prioritises climate action, it will be essential for Sangui Biotech to consider developing and communicating its environmental strategies to align with global climate goals.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Sangui Biotech International, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.


You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.